Shares of Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $37.83.
OMCL has been the topic of a number of research analyst reports. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and raised their price target for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Bank of America boosted their price target on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Wells Fargo & Company increased their price objective on shares of Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. boosted their target price on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Finally, Benchmark restated a “buy” rating and issued a $38.00 target price on shares of Omnicell in a research report on Monday, July 15th.
Read Our Latest Report on Omnicell
Institutional Trading of Omnicell
Omnicell Trading Down 1.7 %
Shares of NASDAQ:OMCL opened at $44.48 on Monday. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $61.44. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. The company has a market cap of $2.05 billion, a PE ratio of -96.70, a P/E/G ratio of 49.29 and a beta of 0.80. The company’s 50-day moving average price is $33.97 and its 200 day moving average price is $30.55.
Omnicell (NASDAQ:OMCL – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The company had revenue of $276.80 million for the quarter, compared to analysts’ expectations of $254.41 million. During the same quarter in the previous year, the company posted $0.29 earnings per share. The business’s revenue for the quarter was down 7.4% compared to the same quarter last year. Sell-side analysts anticipate that Omnicell will post 0.64 earnings per share for the current year.
Omnicell Company Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Recommended Stories
- Five stocks we like better than Omnicell
- Stock Market Upgrades: What Are They?
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- How to Capture the Benefits of Dividend Increases
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Stock Sentiment Analysis: How it Works
- Why Dell Can Continue Winning in AI and Beyond
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.